Mersana Therapeutics Inc

+0.11 (+1.60%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)698.44M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$15.28 Million
Adjusted EPS-$0.48
See more estimates
10-Day MA$6.62
50-Day MA$6.30
200-Day MA$5.82
See more pivots

Mersana Therapeutics Inc Stock, NASDAQ:MRSN

840 Memorial Drive, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.498.0020
Number of Employees: 169


Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.